{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:40:07Z","timestamp":1756305607389,"version":"3.44.0"},"reference-count":17,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,6,10]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>We present a case of antitranscriptional intermediary factor 1 gamma positive dermatomyositis in a patient with metastatic malignant melanoma undergoing therapy with nivolumab. The patient was diagnosed with dermatomyositis after presenting with severe dysphagia, proximal muscle weakness and typical cutaneous and histologic findings. Nivolumab was discontinued, and intravenous and oral steroids, intravenous immunoglobulin and rituximab were initiated for the treatment of dermatomyositis. Both paraneoplastic dermatomyositis in patients with metastatic melanoma and dermatomyositis presenting as an immune-related adverse event in patients receiving immune checkpoint inhibitors (ICI) are rare. In this case, we highlight features that are consistent with both paraneoplastic dermatomyositis and ICI-induced dermatomyositis.<\/jats:p>","DOI":"10.1136\/bcr-2025-265083","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T20:40:30Z","timestamp":1750624830000},"page":"e265083","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["New-onset dermatomyositis in a patient on nivolumab for metastatic melanoma"],"prefix":"10.1136","volume":"18","author":[{"given":"Nina B","family":"Curkovic","sequence":"first","affiliation":[{"name":"Department of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas B","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2462-5051","authenticated-orcid":false,"given":"Eva Rawlings","family":"Parker","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,6,22]]},"reference":[{"key":"2025082707110523000_18.6.e265083.1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"The Lancet"},{"key":"2025082707110523000_18.6.e265083.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2018.56"},{"key":"2025082707110523000_18.6.e265083.3","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/ijd.16151","article-title":"The prognosis of cutaneous malignant melanoma associated with paraneoplastic dermatomyositis","volume":"61","author":"Linhares Leite","year":"2022","journal-title":"Int J Dermatol"},{"key":"2025082707110523000_18.6.e265083.4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CMR.0000000000000642","article-title":"Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature","volume":"30","author":"Kosche","year":"2020","journal-title":"Melanoma Res"},{"key":"2025082707110523000_18.6.e265083.5","doi-asserted-by":"crossref","DOI":"10.5070\/D3268049887","article-title":"Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature","volume":"26","author":"Messer","year":"2020","journal-title":"Dermatol Online J"},{"key":"2025082707110523000_18.6.e265083.6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejca.2018.08.021","article-title":"Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma","volume":"104","author":"Berger","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025082707110523000_18.6.e265083.7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13555-020-00396-6","article-title":"Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma","volume":"10","author":"Lin","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025082707110523000_18.6.e265083.8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2025082707110523000_18.6.e265083.9","doi-asserted-by":"crossref","first-page":"103375","DOI":"10.1016\/j.autrev.2023.103375","article-title":"Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature","volume":"22","author":"Guerra","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2025082707110523000_18.6.e265083.10","doi-asserted-by":"crossref","first-page":"152478","DOI":"10.1016\/j.semarthrit.2024.152478","article-title":"Investigating the disparities among drug categories in drug-induced dermatomyositis: A systematic review","volume":"67","author":"Yu","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025082707110523000_18.6.e265083.11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamadermatol.2023.5418","article-title":"Causes and Clinical Presentation of Drug-Induced Dermatomyositis: A Systematic Review","volume":"160","author":"Caravan","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2025082707110523000_18.6.e265083.12","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"2025082707110523000_18.6.e265083.13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00992","article-title":"Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer","volume":"8","author":"Aussy","year":"2017","journal-title":"Front Immunol"},{"key":"2025082707110523000_18.6.e265083.14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093054","article-title":"Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside","volume":"21","author":"Solimando","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025082707110523000_18.6.e265083.15","article-title":"Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma","volume":"13","author":"Thomas","year":"2021","journal-title":"Cureus"},{"key":"2025082707110523000_18.6.e265083.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02803-5"},{"key":"2025082707110523000_18.6.e265083.17","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology (Oxford)"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-265083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:11:16Z","timestamp":1756303876000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-265083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,22]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bcr-2025-265083"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-265083","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}